Eisai Company, Ltd. (ESALY.PK) , Abbott Japan To Collaborate To Develop D2E7 Anti-rheumatic Agent Seeking Psoriasis Indication
10/19/2005 5:13:16 PM
Tokyo (JCNN) - On April 11, Eisai (TSE: 4523) and Abbott Japan jointly announced that they have concluded a joint development agreement for D2E7, an anti-rheumatic agent owed by Abbott GmbH, the parent company of Abbott Japan. Under the terms of the agreement, the two companies will clinically develop D2E7 seeking an indication for psoriasis.
comments powered by